Japanese drugmaker Eisai today revealed that it has launched its Urece (dotinurad) in China as a treatment for gout. Urece ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

Data suggest that OSA diagnoses were associated with an increased risk for physical and psychological problems in active-duty ...

Visakhapatnam: Eisai Pharma, a noted human health care pharmaceutical company, announced its plans to establish a new global ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Citius Oncology gains FDA approval for Lymphir, targeting a $500M CTCL market. Click here to find out why I think CTOR stock ...

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sl ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...